Unraveling the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma: the "omics" era

被引:0
|
作者
Barchi, Alberto [1 ]
Dell'Anna, Giuseppe [1 ,2 ]
Massimino, Luca [1 ,3 ]
Mandarino, Francesco Vito [1 ]
Vespa, Edoardo [1 ]
Viale, Edi [1 ]
Passaretti, Sandro [1 ]
Annese, Vito [2 ,3 ]
Malesci, Alberto [1 ,2 ]
Danese, Silvio [1 ,3 ]
Ungaro, Federica [1 ]
ENDEAVOR consortium
机构
[1] IRCCS Osped San Raffaele, Gastroenterol & Digest Endoscopy, Milan, Italy
[2] Policlin San Donato, Gastroenterol & Gastrointestinal Endoscopy Unit, IRCCS Policlin San Donato, Milan, Italy
[3] Univ Vita Salute San Raffaele, Fac Med, Milan, Italy
来源
FRONTIERS IN ONCOLOGY | 2025年 / 14卷
关键词
Barrett esophagus; esophageal cancer; metaplasia; omics; genomics; transcriptomics; epigenomics; miRNAs; GENOME-WIDE ASSOCIATION; BODY-MASS INDEX; GASTROESOPHAGEAL-REFLUX; NEOPLASTIC PROGRESSION; EPIGENETIC ALTERATIONS; RESECTED ESOPHAGEAL; RISK; EXPRESSION; DYSPLASIA; BIOMARKERS;
D O I
10.3389/fonc.2024.1458138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Barrett's esophagus (BE) represents a pre-cancerous condition that is characterized by the metaplastic conversion of the squamous esophageal epithelium to a columnar intestinal-like phenotype. BE is the consequence of chronic reflux disease and has a potential progression burden to esophageal adenocarcinoma (EAC). The pathogenesis of BE and EAC has been extensively studied but not completely understood, and it is based on two main hypotheses: "transdifferentiation" and "transcommitment". Omics technologies, thanks to the potentiality of managing huge amounts of genetic and epigenetic data, sequencing the whole genome, have revolutionized the understanding of BE carcinogenesis, paving the way for biomarker development helpful in early diagnosis and risk progression assessment. Genomics and transcriptomics studies, implemented with the most advanced bioinformatics technologies, have brought to light many new risk loci and genomic alterations connected to BE and its progression to EAC, further exploring the complex pathogenesis of the disease. Early mutations of the TP53 gene, together with late aberrations of other oncosuppressor genes (SMAD4 or CKND2A), represent a genetic driving force behind BE. Genomic instability, nonetheless, is the central core of the disease. The implementation of transcriptomic and proteomic analysis, even at the single-cell level, has widened the horizons, complementing the genomic alterations with their transcriptional and translational bond. Increasing interest has been gathered around small circulating genetic traces (circulating-free DNA and micro-RNAs) with a potential role as blood biomarkers. Epigenetic alterations (such as hyper or hypo-methylation) play a meaningful role in esophageal carcinogenesis as well as the study of the tumor micro-environment, which has led to the development of novel immunological therapeutic options. Finally, the esophageal microbiome could be the protagonist to be investigated, deepening our understanding of the subtle association between the host microbiota and tumor development.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Signaling Pathways in the Pathogenesis of Barrett's Esophagus and Esophageal Adenocarcinoma
    Maslenkina, Ksenia
    Mikhaleva, Liudmila
    Naumenko, Maxim
    Vandysheva, Rositsa
    Gushchin, Michail
    Atiakshin, Dmitri
    Buchwalow, Igor
    Tiemann, Markus
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [2] Barrett's esophagus and esophageal adenocarcinoma: pathogenesis, diagnosis, and therapy
    Spechler, SJ
    MEDICAL CLINICS OF NORTH AMERICA, 2002, 86 (06) : 1423 - +
  • [3] Pathogenesis and progression of esophageal adenocarcinoma by prior diagnosis of Barrett's esophagus
    Cook, Michael B.
    Drahos, Jennifer
    Wood, Shannon
    Enewold, Lindsey
    Parsons, Ruth
    Freedman, Neal D.
    Taylor, Philip R.
    Ricker, Winnie
    Abnet, Christian C.
    CANCER RESEARCH, 2015, 75
  • [4] Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma
    Agarwal, Archana
    Polineni, Rahul
    Hussein, Zulfiqar
    Vigoda, Ivette
    Bhagat, Tushar D.
    Bhattacharyya, Sanchari
    Maitra, Anirban
    Verma, Amit
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (05): : 382 - 396
  • [5] Barrett's esophagus and esophageal adenocarcinoma
    Sarisley, Christine
    GASTROENTEROLOGY NURSING, 2008, 31 (01) : 76 - 77
  • [6] Barrett's Esophagus and Esophageal Adenocarcinoma
    Bresalier, Robert S.
    ANNUAL REVIEW OF MEDICINE, 2009, 60 : 221 - 231
  • [7] Barrett's Esophagus and esophageal Adenocarcinoma
    Bloemer, M.
    Jaehne, J.
    CHIRURG, 2013, 84 (03): : 232 - 232
  • [8] Nitric oxide in the molecular pathogenesis of Barrett esophagus and esophageal adenocarcinoma
    Vaninetti, Nadine
    Macdonald, Kimberley
    Geldenhuys, Laurette
    Risch, Harvey
    Porter, Geoffrey
    Guernsey, Duane
    Casson, Alan G.
    GASTROENTEROLOGY, 2007, 132 (04) : A635 - A636
  • [9] Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma
    Alkhayyat, Motasem
    Kumar, Prabhat
    Sanaka, Krishna O.
    Thota, Prashanthi N.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [10] Focus on Barrett's esophagus and esophageal adenocarcinoma
    Paulson, TG
    Reid, BJ
    CANCER CELL, 2004, 6 (01) : 11 - 16